Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study evaluates the use of chemotherapy with cabazitaxel in addition to abiraterone
acetate, prednisone, and leuprolide in neoadjuvant setting prior to radical prostatectomy in
patients with high-risk prostate carcinoma. Half of the participants will receive treatment
with abiraterone acetate, prednisone, leuprolide, and cabazitaxel, while the other half will
receive only abiraterone acetate, prednisone, and leuprolide.